Pfizer of the United States pointed out on the 5th that its oral antiviral drugs for COVID-19 can reduce the risk of hospitalization or death of severely high-risk patients by 89%.
Pfizer of the United States pointed out today that clinical trial results show that its oral antiviral drug Paxlovid for COVID-19 can significantly reduce the risk of hospitalization or death for severely high-risk patients by 89%.
Pfizer pointed out that the results of mid-to-late clinical trials show that Paxlovid has excellent efficacy, and the company will stop recruiting new subjects.
A total of 1,219 unvaccinated adults participated in Pfizer’s clinical trials. They started to get the drug within 3 or 5 days of the onset of symptoms and received 5 days of treatment. The hospitalization rate dropped significantly.
Pfizer began to develop Paxlovid in March 2020, which is a protease inhibitor antiviral therapy that prevents the virus from self-replicating.
